Overcoming Clinical Challenges in BRIC Markets - India
Thomson Reuters Cortellis Competitive Intelligence
4A: In India, the primary driver for clinical trials is cost-savings, which runs upwards of 50 to 60 percent as compared to trials in the U.S. However, government and regulatory rules are changing very quickly, more quickly than foreign pharmaceutical companies can keep up. Guidelines for audio-video recording of informed consent have been implemented, trial registration has been mandated, a call for compulsory accreditation of independent ethics committees has been answered, panels of experts for clinical trial application approval and serious adverse events reviews have been compiled, GCP compliance is being ensured by India’s new clinical trial inspection program, and safety update reports are required to be submitted every six months during the trial. Coupled with lost patent cases by Novartis, Roche, Merck, Gilead, and Pfizer in the country, have led to a decline in trials initiated in India since 2010.
SOURCE: Thomson Reuters Cortellis Competitive Intelligence
Read the full report here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
